ArticleScientific reports2025
Investigating the relationship between peripheral blood transferrin receptor protein and tumor cell ferroptosis, invasion, and metastasis in bladder cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The promising arsenal of ferroptosis inducers in bladder cancer.Journal of molecular medicine (Berlin, Germany) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
This study aimed to investigate the relationship between peripheral blood transferrin receptor protein (TfR) and tumor cell ferroptosis, as well as bladder cancer invasion and metastasis, and further reveal the mechanism of action of TfR in bladder cancer progression. Fifteen patients with bladder cancer, treated at the Department of Urology in our hospital from February 2022 to August 2023, were recruited as research subjects. The patients were aged between 44 and 68 years, with an average age of 52.57 ± 4.38 years. General patient data were analyzed, and the level of peripheral blood TfR was detected at baseline (T0), 3 months (T1), 6 months (T2), and 9 months (T3) post-treatment using a repeated measures design. The levels of GPX4, Ferroportin, and transferrin receptor in the peripheral blood were measured by enzyme-linked immunosorbent assay (ELISA) at T0, T1, T2, and T3. Tumor size and invasiveness were assessed using MRI imaging at the same time points. Protein expressions of MMP-2, MMP-9, and N-Cadherin were analyzed by Western blot at T0, T1, T2, and T3. Pearson correlation analysis was utilized to examine the relationship between TfR, GPX4, Ferroportin, transferrin receptor levels, and tumor invasion and metastasis. As treatment progressed, TfR levels at T3 and T2 were significantly lower than those at T1 and T0 (P < 0.05). Similarly, markers of tumor cell ferroptosis (GPX4, Ferroportin, and transferrin receptor) also showed significant decreases (P < 0.05). Tumor volume at T3 was smaller compared to T0, T1, and T2 (P < 0.05). The protein expressions of MMP-2, MMP-9, and N-Cadherin at T3 and T2 were significantly lower than those at T0 and T1 (P < 0.05). Increased peripheral blood TfR levels and reduced tumor cell ferroptosis were associated with higher cancer cell invasion and metastasis. A reduction in peripheral blood TfR levels is associated with the effectiveness of bladder cancer treatment. This reduction may decrease the invasiveness and migration ability of cancer cells by affecting the iron metabolism pathway. These findings may provide a basis for the development of new targeted therapeutic strategies to improve outcomes for patients with bladder cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.